Table 4.
Anti-angiogenic activity of isolated compounds in human EPCs
| compound | IC50 (µM) a |
|---|---|
| 1 | > 50 |
| 2 | > 50 |
| 3 | > 50 |
| 4 | > 50 |
| 5 | 5.6 ± 0.1 |
| 6 | > 50 |
| 7 | > 50 |
| 8 | 4.6 ± 0.1 |
| 9 | 8.1 ± 0.4 |
| 10 | 0.8 ± 0.3 |
| 11 | 5.2 ± 0.3 |
| 12 | 2.9 ± 0.3 |
| 13 | > 50 |
| 14 | > 50 |
| Sorafenib b | 4.8 ± 0.3 |
aEPCs were treated with the indicated compounds for 48 h. Anti-angiogenic effects were evaluated in a cell growth assay (n = 3). Data are displayed as the mean ± SEM
bPositive control used in this study